Literature DB >> 10445048

Novel small molecule nonpeptide aminopeptidase n inhibitors with a cyclic imide skeleton.

R Shimazawa1, H Takayama, Y Fujimoto, M Komoda, K Dodo, R Yamasaki, R Shirai, Y Koiso, K Miyata, F Kato, M Kato, H Miyachi, Y Hashimoto.   

Abstract

A novel series of small molecule nonpeptide aminopeptidase N (APN) inhibitors with a N-phenylphthalimide or N-phenylhomophthalimide skeleton were prepared. Evaluation of their protease inhibitory activities revealed that (i) some N-phenylphthalimide analogs are potent APN inhibitors, but they are also inhibitors of another protease, dipeptidylpeptidase IV (DPP-IV), and (ii) some N-phenylhomophthalimide analogs, including 2-(2,6-diethylphenyl)-1,2,3,4-tetrahydroisoquinoline-1,3-dione (PIQ-22), are potent and specific inhibitors of APN without DPP-IV-inhibitory activity. The structure-activity relationship studies of N-phenylphthalimides and N-phenylhomophthalimides are reviewed. PIQ-22 showed potent tumor-cell invasion-inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10445048     DOI: 10.3109/14756369909030321

Source DB:  PubMed          Journal:  J Enzyme Inhib        ISSN: 1026-5457


  3 in total

1.  The Rational Design of Therapeutic Peptides for Aminopeptidase N using a Substrate-Based Approach.

Authors:  Shilvi Joshi; Lang Chen; Michael B Winter; Yi-Lun Lin; Yang Yang; Mariya Shapovalova; Paige M Smith; Chang Liu; Fang Li; Aaron M LeBeau
Journal:  Sci Rep       Date:  2017-05-02       Impact factor: 4.379

Review 2.  Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.

Authors:  Brigitte Bauvois; Daniel Dauzonne
Journal:  Med Res Rev       Date:  2006-01       Impact factor: 12.944

3.  Design, synthesis and primary activity evaluation of L-arginine derivatives as amino-peptidase N/CD13 inhibitors.

Authors:  Jiajia Mou; Hao Fang; Fanbo Jing; Qiang Wang; Yingzi Liu; Huawei Zhu; Luqing Shang; Xuejian Wang; Wenfang Xu
Journal:  Bioorg Med Chem       Date:  2009-05-03       Impact factor: 3.641

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.